Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) says it could potentially receive more than $1 billion from a partnership with Japan's Takeda Pharmaceutical Co. on potential weight-loss treatments, according to Associated Press.
Company shares climbed nearly 10 percent in trading Monday, despite an announcement that government regulators strengthened warning labels on company's diabetes treatment Byetta.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter.
The Food and Drug Administration highlighted bolstered language about kidney damage on the drug's labeling.
Amylin, based in San Diego, said late Sunday it will receive $75 million upfront from Takeda and said future payments for development and achieving commercial milestones could top $1 billion.
The deal includes two potential weight-loss treatments, a pramlintide-metreleptin combination and davalintide. Both potential drugs are in midstage, or Phase II, clinical development. In July, Amylin said pramlintide-metreleptin prompted an average weight loss of 22 pounds, or 11 percent of patients' body weight, during a midstage study.
The deal also includes additional compounds from both companies research programs. Aside from milestone payments, Amylin is also eligible for royalties on global sales.
Its shares rose $1.09, or 9.9 percent, to close at $12.13 Monday.
Amylin is responsible for developing potential products through midstage development, while Takeda will take over late-stage development, along with all development activities outside the U.S.
Amylin estimates it will be responsible for 20 percent of development costs for obtaining approval for products in the U.S.
On Friday, Amylin said the FDA expanded approval of Byetta as a stand-alone diabetes treatment. Previously, it was approved for use in combination with other diabetes drugs.
The FDA also strengthened warning language on Byetta, following more than 60 reports of kidney failure with the drug between April 2005 and October 2008.
While the previous label mentioned such side effects, the new language specifies that doctors should not prescribe Byetta to patients with severe kidney problems. The FDA did not put the warning in a so-called "black box," a move that could have raised safety concerns among doctors.
The Amylin-Takeda deal comes amid a surge in obesity treatment research and development from the biotechnology industry. Several companies already have their potential drugs in late-stage development, setting the stage for a competitive market if each gains Food and Drug Administration approval.
In October, several companies reported positive updates to their studies at the annual scientific meeting of The Obesity Society in Washington DC.
Vivus Inc. (NASDAQ: VVUS) said patients taking its potential weight-loss drug Qnexa lost about 11 percent of their body weight. Arena Pharmaceuticals Inc. (NASDAQ: ARNA) said patients taking lorcaserin lost 31 percent of their excess body weight in the first year of a two-year study. Earlier this year, Orexigen Therapeutics Inc. (NASDAQ: OREX) reported results showing that Contrave patients lost more than 8 percent of their weight.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
